Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma
Open Access
- 21 October 2009
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 85 (1), 87-90
- https://doi.org/10.1002/ajh.21571
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- The biology of Hodgkin's lymphomaNature Reviews Cancer, 2008
- Lenalidomide-Associated Tumor Flare Reaction Is Manageable in Patients With Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2008
- Free immunoglobulin light chains: a novel target in the therapy of inflammatory diseasesTrends in Pharmacological Sciences, 2008
- The evolving use of serum free light chain assays in haematologyBritish Journal of Haematology, 2008
- Lenalidomide for the Treatment of B-Cell MalignanciesJournal of Clinical Oncology, 2008
- Managing relapsed and refractory Hodgkin lymphomaBritish Journal of Haematology, 2008
- High serum levels of B‐lymphocyte stimulator are associated with clinical–pathological features and outcome in classical Hodgkin lymphomaBritish Journal of Haematology, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor CellsCancer Research, 2007
- Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II StudyJournal of Clinical Oncology, 2006